At 22.1% CAGR, the South & Central America Organoids Market is projected to be worth US$ 654.25 million by 2030, says Business Market Insights

According to Business Market Insights research, the South & Central America Organoids market was valued at US$ 132.38 million in 2022 and is expected to reach US$ 654.25 million by 2030, registering a CAGR of 22.1% from 2022 to 2030. Combining organoid with organ-on-a-chip is the critical factor attributed to the South & Central America Organoids market expansion.        

Organoid and organ-on-a-chip, which serve as evolving pathological and human physiological relevant in vitro models, have the potential to revolutionize the conventional paradigm of cancer research and produce real clinical benefits. The recent inclination in the collaborative application of organoids with organ-on-a-chip and 3D bioprinting enables the development of sophisticated cancer models to study underlying mechanisms of tumor-stroma interactions, multiorgan tumor metastasis, and cancer-microenvironment interactions. By incorporating multiple organoids into organ-on-a-chip, organoid-on-a-chip can inherit benefits of both organoid and organ-on-a-chip and provide a valuable tool to study multiorgan tumor metastases and cancer-microenvironment interactions.

In addition, technological advancements will facilitate various applications in biological and biomedical fields for disease modeling and clinical drug screening by combining organoids with organ-on-a-chip. Technological advancements have enabled the development of brain organoids-on-chip, liver organoids-on-chip, intestine organoids-on-chip, and more. Although organoid-on-a-chip is currently a developing field, much scope exists for improvement. Thus, it will also require cooperative efforts from interdisciplinary researchers to reach organoids' full utility in human biomedical studies and lead the market’s growth in the coming future.

On the contrary, issues related to incorporation of organoids into existing workflows and dearth of skilled professionals hampers the South & Central America organoids market.  

Based on organ type, the South & Central America organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held 23.0% share of South & Central America organoids market in 2022, amassing US$ 30.49 million. It is projected to garner US$ 147.92 million by 2030 to expand at 21.8% CAGR during 2022–2030.   

Based on application, the South & Central America organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held 29.7% share of South & Central America organoids market in 2022, amassing US$ 39.36 million. It is projected to garner US$ 203.58 million by 2030 to expand at 22.8% CAGR during 2022–2030.

Based on source, the South & Central America organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held 71.9% share of South & Central America organoids market in 2022, amassing US$ 95.16 million. It is projected to garner US$ 485.25 million by 2030 to expand at 22.6% CAGR during 2022–2030.

Based on type, the South & Central America organoids market is segmented into instruments, consumables, and services. The consumables segment held 61.0% share of South & Central America organoids market in 2022, amassing US$ 80.78 million. It is projected to garner US$ 419.35 million by 2030 to expand at 22.9% CAGR during 2022–2030.

Based on country, the South & Central America organoids market has been categorized into the Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 65.9% share of South & Central America organoids market in 2022. It was assessed at US$ 87.29 million in 2023 and is likely to hit US$ 439.53 million by 2030, exhibiting a CAGR of 22.4% during 2022–2030.

Key players operating in the South & Central America organoids market are Cellesce, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, among others.   

• In Feb 2023, the collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com